Barclays’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-10,000
| Closed | -$3.98M | – | 5018 |
|
|
2025
Q4 | $3.98M | Buy |
+10,000
| New | +$4.43M | ﹤0.01% | 2396 |
|
|
2025
Q2 | – | Sell |
-9,000
| Closed | -$2.43M | – | 5235 |
|
|
2025
Q1 | $2.43M | Sell |
9,000
-35,500
| -80% | -$9.12M | ﹤0.01% | 2482 |
|
|
2024
Q4 | $10.5M | Sell |
44,500
-11,800
| -21% | -$3.1M | ﹤0.01% | 1535 |
|
|
2024
Q3 | $15.5M | Buy |
+56,300
| New | +$14.7M | ﹤0.01% | 1207 |
|
|
2024
Q2 | – | Sell |
-60,200
| Closed | -$9M | – | 4835 |
|
|
2024
Q1 | $9M | Hold |
60,200
| – | – | ﹤0.01% | 1469 |
|
|
2023
Q4 | $11.5M | Buy |
+60,200
| New | +$10.3M | ﹤0.01% | 1417 |
|
|
2023
Q1 | – | Sell |
-41,000
| Closed | -$9.74M | – | 5070 |
|
|
2022
Q4 | $9.74M | Buy |
+41,000
| New | +$8.75M | ﹤0.01% | 1221 |
|
|
2022
Q1 | – | Sell |
-900
| Closed | -$153K | – | 4906 |
|
|
2021
Q4 | $153K | Buy |
+900
| New | +$167K | ﹤0.01% | 3636 |
|
|
2021
Q1 | – | Sell |
-6,900
| Closed | -$897K | – | 4664 |
|
|
2020
Q4 | $897K | Sell |
6,900
-17,400
| -72% | -$2.32M | ﹤0.01% | 2828 |
|
|
2020
Q3 | $3.54M | Sell |
24,300
-21,800
| -47% | -$3.1M | ﹤0.01% | 1644 |
|
|
2020
Q2 | $6.83M | Sell |
46,100
-28,000
| -38% | -$3.77M | 0.01% | 1167 |
|
|
2020
Q1 | $8.07M | Sell |
74,100
-25,800
| -26% | -$2.98M | 0.01% | 1130 |
|
|
2019
Q4 | $11.5M | Buy |
99,900
+44,900
| +82% | +$4.48M | 0.01% | 1286 |
|
|
2019
Q3 | $4.42M | Buy |
55,000
+22,000
| +67% | +$1.74M | ﹤0.01% | 1974 |
|
|
2019
Q2 | $2.39M | Buy |
33,000
+20,100
| +156% | +$1.54M | ﹤0.01% | 2687 |
|
|
2019
Q1 | $1.21M | Sell |
12,900
-33,300
| -72% | -$2.79M | ﹤0.01% | 3196 |
|
|
2018
Q4 | $3.37M | Sell |
46,200
-32,700
| -41% | -$2.52M | ﹤0.01% | 1903 |
|
|
2018
Q3 | $6.91M | Buy |
78,900
+24,900
| +46% | +$2.5M | ﹤0.01% | 1518 |
|
|
2018
Q2 | $5.32M | Buy |
54,000
+15,100
| +39% | +$1.5M | ﹤0.01% | 1677 |
|
|
2018
Q1 | $4.63M | Sell |
38,900
-136,200
| -78% | -$17.6M | ﹤0.01% | 1695 |
|
|
2017
Q4 | $22.2M | Sell |
175,100
-138,100
| -44% | -$17.4M | 0.02% | 753 |
|
|
2017
Q3 | $36.8M | Buy |
313,200
+105,600
| +51% | +$9.01M | 0.04% | 419 |
|
|
2017
Q2 | $16.6M | Buy |
207,600
+100,100
| +93% | +$6.4M | 0.02% | 696 |
|
|
2017
Q1 | $5.51M | Buy |
107,500
+27,700
| +35% | +$1.28M | 0.01% | 1263 |
|
|
2016
Q4 | $2.99M | Buy |
79,800
+71,000
| +807% | +$2.97M | ﹤0.01% | 1800 |
|
|
2016
Q3 | $596K | Sell |
8,800
-9,600
| -52% | -$677K | ﹤0.01% | 3079 |
|
|
2016
Q2 | $1.02M | Sell |
18,400
-41,400
| -69% | -$2.61M | ﹤0.01% | 2595 |
|
|
2016
Q1 | $3.71M | Buy |
59,800
+50,800
| +564% | +$3.38M | 0.01% | 1408 |
|
|
2015
Q4 | $846K | Sell |
9,000
-7,600
| -46% | -$705K | ﹤0.01% | 2761 |
|
|
2015
Q3 | $1.33M | Buy |
16,600
+1,500
| +10% | +$167K | ﹤0.01% | 2465 |
|
|
2015
Q2 | $1.8M | Sell |
15,100
-14,700
| -49% | -$1.76M | ﹤0.01% | 2309 |
|
|
2015
Q1 | $3.1M | Buy |
29,800
+28,200
| +1,763% | +$2.86M | ﹤0.01% | 1938 |
|
|
2014
Q4 | $155K | Sell |
1,600
-8,900
| -85% | -$825K | ﹤0.01% | 4838 |
|
|
2014
Q3 | $819K | Buy |
10,500
+7,700
| +275% | +$497K | ﹤0.01% | 3536 |
|
|
2014
Q2 | $176K | Sell |
2,800
-170,700
| -98% | -$10.1M | ﹤0.01% | 4933 |
|
|
2014
Q1 | $11.6M | Buy |
173,500
+152,900
| +742% | +$11.8M | 0.01% | 1041 |
|
|
2013
Q4 | $1.32M | Sell |
20,600
-66,200
| -76% | -$3.95M | ﹤0.01% | 3086 |
|
|
2013
Q3 | $5.55M | Buy |
86,800
+78,500
| +946% | +$3.91M | 0.01% | 1599 |
|
|
2013
Q2 | $257K | Buy |
+8,300
| New | +$221K | ﹤0.01% | 4933 |
|
Other funds holding ALNY
VPM
VCM
Barclays's ALNY Position: Q1 2026 in Review
Barclays reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.87% in Q1 2026, selling an estimated $659K and leaving 220,623 shares worth $73M. The position accounts for 0.02% of the portfolio, ranked #602.
Barclays first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $88.5M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Barclays held 220,623 shares of Alnylam Pharmaceuticals worth $73M as of Q1 2026.
- Barclays sold 1,938 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $659K.
- Alnylam Pharmaceuticals made up 0.02% of Barclays's portfolio in Q1 2026, its #602 holding.
- Barclays first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Alnylam Pharmaceuticals position peaked at $88.5M in Q4 2025.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.